Seattle Children’s is now offering the Pfizer-BioNTech COVID-19 updated (bivalent*) booster vaccine and the Moderna bivalent booster vaccine to our patients, workforce members and community members. Individuals can receive a bivalent booster dose if it has been at least two months since they completed their primary COVID-19 vaccination series or have received the most recent booster dose with any authorized or approved single-strain (monovalent) COVID-19 vaccine.
Read full post »
Lower-Body Gender-Affirming Surgery
Seattle Children’s is now offering gender-affirming surgeries for the lower body to patients age 18 and older who have a diagnosis of gender dysphoria, in addition to the gender-affirming surgical services we previously offered such as chest reconstruction and facial gender-affirming surgery. This expansion will further Seattle Children’s commitment to supporting transgender and nonbinary patients.
Read full post »
Beginning in fall 2022, pediatric, adolescent and young adult patients with cancer and blood disorders in the greater Pacific Northwest will be cared for at a new state-of-the-art facility specifically designed for transformative, patient-centered care.
Read full post »
Starting today, Seattle Children’s is offering appointments to children between the ages of 6 months and 5 years (under 6 years old) to receive the Pfizer-BioNTech and Moderna COVID-19 vaccines, based on recent approvals from the CDC, Washington State Department of Health and the Western States Scientific Safety Review Workgroup. We are grateful to be able to offer COVID-19 vaccines to young patients.
Read full post »
We are pleased to announce the launch of a new intensive outpatient program (IOP) at Seattle Children’s for patients with eating disorders. The Eating Disorders IOP is designed for children and youth with high-acuity eating disorders who don’t require inpatient care but need more than typical outpatient care can provide.
Read full post »
Seattle Children’s Therapeutics has opened a new study that will evaluate the safety and feasibility of CAR T-cell immunotherapy in patients with bone cancer. The ENLIGHTen-01 study is approved for patients ages 15 to 30 years old who have refractory or progressive osteosarcoma. It is Seattle Children’s first study of CAR T-cell therapy for this patient population.
Read full post »
Provider Grand Rounds
Year-round on Thursdays from 8 to 9 a.m. Learn more.
Read full post »
From: Dr. Jay Santos, Urgent Care Medical Director and Dr. Tony Woodward, ED Medical Director
- We continue to experience extreme high volumes in the ED and our urgent care clinics (UCs).
- Please use the Emergency or Urgent Care Referral Guide when referring patients.
- When referring a patient to the ED, please call the ED Communications Center at 206-987-8899 to alert us they are coming.
Read full post »
We’re excited to announce a June 1, 2022 opening for the first finished spaces of Seattle Children’s much-anticipated new addition — formerly called Building Care during construction and now referred to as Forest B (our buildings’ zones are Forest, Mountain, River and Ocean). The finished spaces include a parking garage for patients and families and a new main lobby that will serve as our 24/7 main entrance. The current main entrance will still be open to patients and families daily until 10 p.m.
Read full post »
